コンテンツにジャンプ
先端医療開発センター

トップページ > グループ紹介 > ゲノムトランスレーショナルリサーチ分野(築地) > 業績

業績

2017年

  1. Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir Med. 5:42-50, 2017.
  2. George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Petersen I, Jang SJ, Buttners R, Harris CC, Yokota J, Thomas RK, Kohno T. Genomic amplification of CD274 (PD-L1) in small cell lung cancer. Clin Cancer Res. 23(5):1220-1226, 2017.
  3. Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. Oncotarget. 8(8):12941-12952, 2017.
  4. Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto Y, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas. 46(3):335-340, 2017.
  5. 河野隆志、角南久仁子. がんのゲノム医療 -進行がんの治療選択のためのクリニカルシーケンシング- Medical Science Digest (2017-2月号), 2017.
  6. 久保崇、河野隆志. パラフィン包埋標本を用いたがんクリニカルシークエンスの試み. 病理と臨床, 35: 653-659, 2017.
  7. 河野隆志. クリニカルシークエンスによるがんの遺伝子プロファイリング検査と知識ベースの役割. BioClinica, 32, 23-28, 2017.

2016年

  1. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer, 15:73, 2016
  2. Asao T, Fujiwara Y, Sunami K, Kitahara S, Goto Y, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Ichikawa H, Kohno T, Tsuta K, Watanabe S, Takahashi K, Ohe Y. Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. Lung Cancer, 93:77-81, 2016
  3. Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. Oncologist, 21:156-164, 2016
  4. Sunami K, Furuta K, Tsuta K, Sasada S, Izumo T, Nakaoku T, Shimada Y, SaitoM, Nokihara H, Watanabe S, Ohe Y, Kohno T. Multiplex diagnosis of oncogenic fusion and MET exon skipping by molecular counting using formalin-fixed paraffin embedded lung adenocarcinoma tissues. J Thorac Oncol. 11:203-12, 2016
  5. Kamata T, Sunami K, Yoshida A, Shiraishi K, Furuta K, Shimada Y, Katai H,Watanabe S, Asamura H, Kohno T, Tsuta K. Frequent BRAF or EGFR mutations in ciliated muconodular papillary tumors of the lung. J Thorac Oncol. 11:261-5, 2016
  6. 角南 久仁子:がん診療における治療選択のためのクリニカルシーケンシング, 病理と臨床, 34巻臨時創刊号, p.311-316, 2016

2015年

  1. Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome Biol, 16:66, 2015.
  2. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res, 4:156-164, 2015.
  3. Saito M, Shimada Y, Shiraishi K, Sakamoto H, Tsuta K, Totsuka H, Chiku S, Ichikawa H, Kato M, Watanabe S, Yoshida T, Yokota J, Kohno T. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Cancer Res, 75:2264-2271, 2015.